RxDoctor Payments DataLook up a doctor →

Katie Creighton, NP

Family · Annapolis, MDNPI 1467717298

Payments from drug & device makers

$9,678in general payments, 2019–2025

Across 421 payments — averaging $22.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Novo Nordisk$563
  • Amgen$551
  • GSK$544
  • Bayer$501
  • plus $5K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie76$1,289
AstraZeneca(2 entities)27$1,122
Novo Nordisk25$563
Amgen(2 entities)29$551
GSK21$544
Bayer23$501
Pfizer23$501
Sumitomo Pharma America, Inc.14$437
Otsuka America Pharmaceutical, Inc.9$277
Lilly USA, LLC12$249
Astellas Pharma US Inc9$224
Biohaven Pharmaceuticals, Inc.6$216
Boehringer Ingelheim11$194
Novartis10$189
Nevro Corp.5$186
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$170
Harmony Biosciences LLC3$160
Sunovion Pharmaceuticals Inc.9$158
Biogen6$142
Corcept Therapeutics6$139
Teva Pharmaceuticals USA, Inc.6$135
Kowa Pharmaceuticals America, Inc.7$116
Esperion Therapeutics, Inc.5$114
Urovant Sciences Inc1$107
Axsome Therapeutics, Inc.4$101
Lundbeck LLC5$93
Merck4$83
Shield Therapeutics Inc4$66
Silk Road Medical, Inc.2$66
Amneal Pharmaceuticals LLC4$64
Idorsia Pharmaceuticals US Inc3$63
Mylan Specialty L.p.3$57
Phathom Pharmaceuticals, Inc.4$55
Vanda Pharmaceuticals Inc.2$53
Genentech USA, Inc.3$51
Acadia Pharmaceuticals Inc2$50
Biohaven Pharmaceutical Holding Company Ltd.2$43
Organogenesis Inc.1$42
Eisai Inc.2$42
Xeris Pharmaceuticals, Inc.2$35
Digestive Care, Inc.1$33
Amarin Pharma, Inc.2$33
Inspire Medical Systems, Inc.1$29
Gilead1$26
Kyowa Kirin, Inc.1$24
Verona Pharma, Inc.1$23
Phadia US Inc.1$22
Neos Therapeutics, LP1$20
Dexcom, Inc.1$20
Takeda Pharmaceuticals U.S.A., Inc.1$19
Abbott1$18
Johnson & Johnson1$18
Eyevance Pharmaceuticals LLC1$18
Hikma Pharmaceuticals USA1$18
TMS Neurohealth Centers Inc.1$17
Corium, LLC1$17
Ironwood Pharmaceuticals, Inc1$16
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$15
Avanir Pharmaceuticals, Inc.1$15
Currax Pharmaceuticals LLC1$15

How this compares

$9,678 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland →

Medicare billing

Part B allowed, 2024
$90,412
Medicare patients
310
Services billed
1,185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family in Annapolis

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →